<DOC>
	<DOCNO>NCT00496483</DOCNO>
	<brief_summary>A three sequence , open-label , multi-center , prospective , study stable kidney transplant patient assess compare pharmacokinetics ( Cmax , C24 , AUC ) , safety LCP-Tacro ( tacrolimus ) tablets versus Prograf ( tacrolimus ) capsule .</brief_summary>
	<brief_title>Pharmacokinetics LCP-Tacro Stable Kidney Transplant Patients</brief_title>
	<detailed_description>A three sequence , open-label , multi-center , prospective , study stable kidney transplant patient assess compare pharmacokinetics ( Cmax , C24 , AUC ) , safety LCP-Tacro ( tacrolimus ) tablets versus Prograf ( tacrolimus ) capsule . Stable kidney transplant patient fulfill I/E criterion enrol keep Prograf 7 day . Following 24-hour PK study Day 7 determine pharmacokinetics Prograf , patient convert daily LCP-Tacro 7 day dose change allow . On Day 14 Day 21 24-hour LCP-Tacro PK study perform . On Day 22 patient convert back original twice daily dose Prograf safety follow-up period 30 day end safety assessment day 53 .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Men woman 1865 year age recipients renal transplant least 6 month prior enrollment Patients oral Prograf therapy part maintenance immunosuppression therapy , stable dos trough level tacrolimus 712 ng/mL least two week prior enrollment . Patients maintain concurrent immunosuppression mycophenolate mofetil ( MMF , CellCept ) mycophenolic acid delayedrelease tablet ( Myfortic ) , stable dos least two week prior enrollment Patients serum creatinine &lt; 2.0mg/dL prior enrollment Able swallow study medication Patients capable understanding purpose risk study , give write informed consent willing participate comply study Women childbearing potential must negative serum pregnancy test within seven day prior receive study medication Patients successfully pass drug screen Recipients transplant organ kidney White blood cell count &lt; 2.8 x 10^9 /L Patients receive total dose Prograf 24 hour &lt; 3mg Patients unable unwilling provide inform consent Pregnant nursing woman Patients reproductive potential unwilling/unable use double barrier method contraception Administration investigational agent three month prior enrollment Patient receive drug interfere tacrolimus metabolism Patients take sirolimus within past three month prior screen Patient episode acute cellular require antibody therapy within 6 month prior enrollment Patient treat acute cellular rejection within 30 day prior enrollment Patient HCV negative receive HCV positive ( HCV RNA PCR HCV antibody ) donor kidney Patient current malignancy history malignancy ( within past 5 year ) , except basal nonmetastatic squamous cell carcinoma skin treat successfully Patient uncontrolled concomitant infection , systemic infection require treatment , unstable medical condition could interfere study objective Patient severe diarrhea , vomit , active peptic ulcer gastrointestinal disorder may affect absorption tacrolimus Patient require therapy immunosuppressive agent prescribe study Patient know hypersensitivity corticosteroid , mycophenolate mofetil , mycophenolic acid tacrolimus Patient form current substance abuse , psychiatric disorder condition , opinion Investigator , may invalidate communication Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Kidney Transplantation</keyword>
</DOC>